Cluster Headache Treatment With Rimegepant
NCT05264714 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2026-01-12
Summary
The purpose of this research is to explore the efficacy of rimegepant as a preventative therapy for cluster headache.
Conditions
- Cluster Headache
Interventions
- DRUG
-
Rimegepant
150 mg oral disintegrating tablet every other day for one week
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Carrie Robertson, MD · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-07
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Consistency of Response With Rimegepant in Acute Treatment of Migraine
NCT06898047 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
NCT05399459 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT05207865 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 ·Status: RECRUITING ·Phase: PHASE3
-
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
NCT06467370 ·Status: COMPLETED
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
NCT06532357 ·Status: COMPLETED
-
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
NCT03732638 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
NCT01430442 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
NCT00806546 ·Status: COMPLETED ·Phase: PHASE3
-
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
NCT00898677 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·Status: RECRUITING ·Phase: PHASE3
-
A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
NCT06221267 ·Status: COMPLETED
-
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
NCT05127486 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Safety Study in Acute Treatment of Migraine
NCT03266588 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832 ·Status: RECRUITING
-
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
NCT02619617 ·Status: TERMINATED ·Phase: PHASE2
-
The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China
NCT06728345 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
NCT00894556 ·Status: COMPLETED ·Phase: PHASE3
-
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
NCT06412965 ·Status: COMPLETED
-
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
NCT00095004 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Erenumab on Functional Impact of Migraine
NCT04465357 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
NCT00516737 ·Status: COMPLETED ·Phase: PHASE3